Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11304376 | 0.84 | LMNA (0.69) | ALDH1A1RAB9ASIGMAR1GID4KDM4E | |
| SCHEMBL3213006 | 0.82 | LMNA (0.69) | ALDH1A1RAB9ASIGMAR1SMN1; SMN2LMNA | |
| SCHEMBL31248387 | 0.78 | L3MBTL1 (0.60) | ALDH1A1GID4KDM4ECTDSP1POLB | |
| SCHEMBL19254905 | 0.76 | SMN1; SMN2 (0.72) | ALDH1A1RAB9ASIGMAR1SMN1; SMN2LMNA | |
| SCHEMBL15678797 | 0.75 | HDAC1 (0.56) | ALDH1A1RAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL841278 | 0.74 | L3MBTL1 (0.50) | KMT2AMEN1 | |
| SCHEMBL30662307 | 0.74 | SMN1; SMN2 (0.74) | ALDH1A1RAB9ASIGMAR1SMN1; SMN2LMNA | |
| SCHEMBL15678794 | 0.74 | HDAC1 (0.58) | ALDH1A1RAB9ASMN1; SMN2KDM4ENPC1 | |
| SCHEMBL839589 | 0.73 | KMT2A (0.47) | ALDH1A1LMNAPOLBKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL20658835 | 0.73 | L3MBTL1 (0.49) | LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| US-8507521-B2 | Heterocyclic derivatives | Merck Sharp + Dohme B.V. (NL) | 2013-08-13 | — | — | US | disclosed |
| EP-2496569-A2 | HETEROCYCLIC DERIVATIVES | MSD Oss B.V. (NL) | 2012-09-12 | — | — | EP | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2012-08-30 | — | — | US | disclosed |
| US-7960560-B2 | 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| WO-2011051490-A2 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051490-A2 | HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2011-05-05 | — | — | WO | disclosed |
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | N. V. ORGANON | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | OPRM1, OR10J3, OPRD1 | ALDH1A1 3054/4885RAB9A 2526/4885SIGMAR1 34/4885 |
| US-20120220622-A1 | HETEROCYCLIC DERIVATIVES | GRIN2C, GRIN3A, GRIN2D | ALDH1A1 118/4885RAB9A 1781/4885SIGMAR1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.